Windtree Therapeutics (NASDAQ:WINT) Trading Down 2.2%

Windtree Therapeutics, Inc. (NASDAQ:WINT) shares were down 2.2% during trading on Wednesday . The stock traded as low as $0.92 and last traded at $0.92. Approximately 121,348 shares changed hands during trading, a decline of 67% from the average daily volume of 362,965 shares. The stock had previously closed at $0.94.

Windtree Therapeutics Price Performance

The company’s fifty day moving average is $1.07 and its 200 day moving average is $1.27. The firm has a market cap of $4.74 million, a price-to-earnings ratio of -0.05 and a beta of 0.20. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 2.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in Windtree Therapeutics during the second quarter worth $27,000. Envestnet Asset Management Inc. boosted its holdings in Windtree Therapeutics by 894.7% during the third quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after purchasing an additional 96,515 shares during the last quarter. Millennium Management LLC boosted its holdings in Windtree Therapeutics by 411.1% during the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after purchasing an additional 64,232 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Windtree Therapeutics during the second quarter worth $39,000. Finally, Virtu Financial LLC acquired a new position in Windtree Therapeutics during the second quarter worth $54,000. Institutional investors and hedge funds own 21.98% of the company’s stock.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.